Home / News Briefs / Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

finance.yahoo.com – FOR EU TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX AND THE UK

Tweeted by @Tagggly https://twitter.com/Tagggly/status/1343472063500185600

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.